EPHOS-B
Phase 3 Unknown
257 enrolled
TACT2
Phase 3 Unknown
4,400 enrolled
Study of Preoperative Chemotherapy for Early Triple Negative or HER2-positive Operable Breast Cancer
Phase 2 Unknown
230 enrolled
Breast-Conserving Therapy in Patients With Triple-Negative Breast Cancer
Phase NA Unknown
464 enrolled
Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer
Phase NA Unknown
75 enrolled
Tamoxifen in Treating Women With Breast Cancer
Phase 3 Unknown
20,000 enrolled
Epirubicin and Tamoxifen With or Without Docetaxel in Treating Postmenopausal Women With Breast Cancer
Phase 3 Unknown
Trastuzumab or Observation After Combination Chemotherapy and Trastuzumab in Treating Patients Undergoing Surgery for Stage II or Stage III Breast Cancer
Phase 2 Unknown
160 enrolled
Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma
Phase 3 Unknown
Doxorubicin or Epirubicin and Cyclophosphamide in Treating Older Women With Invasive Breast Cancer
Phase 3 Unknown
1,000 enrolled
Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer
Phase 3 Unknown
2,500 enrolled
Chemotherapy and/or Hormone Therapy With or Without Zoledronate in Treating Women With Stage II or Stage III Breast Cancer
Phase 3 Unknown
Cyclophosphamide, Methotrexate, and Fluorouracil, With or Without Epirubicin Hydrochloride, in Treating Women Who Have Undergone Surgery for Breast Cancer (Group III Closed to New Patients as of 12/7/2009)
Phase 3 Unknown
800 enrolled
Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery
Phase 2 Unknown
94 enrolled
Lymph Node Radiation Therapy in Patients With Stage I, Stage II, or Stage III Breast Cancer That Has Been Surgically Removed
Phase 3 Unknown
4,000 enrolled
Combination Chemotherapy in Treating Women With Resected Breast Cancer
Phase 2 Unknown
Adjuvant Radiation Therapy Compared With Observation After Surgery in Treating Women With Estrogen Receptor Positive or Progesterone Receptor Positive Ductal Carcinoma In Situ of the Breast Who Are Receiving Tamoxifen or Anastrozole
Phase 2 Unknown
2,000 enrolled